ArticleThe Journal of antibiotics2021
Inhibitory effect of berberine hydrochloride against Candida albicans and the role of the HOG-MAPK pathway.
Article in The Journal of antibiotics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Berberine as a Promising Antifungal Agent: Insights into Molecular Mechanisms and Therapeutic Potential.ACS omega · 2026Review
- Aloe emodin disrupts Candida albicans mitochondrial iron homeostasis against its hyphal development and oral candidiasis.Applied microbiology and biotechnology · 2026Article
- Research Progress in the Treatment of Vaginitis With Bioactive Compounds: Targeting of Vaginal Microflora.MicrobiologyOpen · 2026Review
- Dual Biological Effects and Mechanisms of Gut Microbiota in Breast Cancer: A Review.Current pharmaceutical biotechnology · 2026Review
- Inhibitory effects of berberine on Fonsecaea monophora in vitro and in vivo.BMC complementary medicine and therapies · 2025Article
- Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles.Pharmaceutics · 2025Article
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Baicalin promotes β-1,3-glucan exposure inFrontiers in cellular and infection microbiology · 2024Article
- The potential role of plant secondary metabolites on antifungal and immunomodulatory effect.Applied microbiology and biotechnology · 2023Review
- The Impact of Berberine Loaded Selenium Nanoparticles onArchives of Razi Institute · 2023Article
- The effect of herbal medicine in innate immunity toFrontiers in immunology · 2023Review
- Antifungal and Immunomodulatory Ingredients from Traditional Chinese Medicine.Antibiotics (Basel, Switzerland) · 2022Review
- The Antimicrobial Peptide AMP-17 Derived fromAntibiotics (Basel, Switzerland) · 2022Article
- Targeting Virulence Factors ofFoods (Basel, Switzerland) · 2022Review
- Anticancer Effects and Mechanisms of Berberine from Medicinal Herbs: An Update Review.Molecules (Basel, Switzerland) · 2022Review
- Oxidative stress response pathways in fungi.Cellular and molecular life sciences : CMLS · 2022Review
- Magnolol as a potent antifungal agent inhibitsFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine hydrochloride (BH), an active component of Coptis chinensis and other plant taxa, has broad antimicrobial activity and may be useful for the treatment of Candida infections. In this study, the mechanisms underlying the inhibitory effect of BH against Candida albicans were evaluated, with a focus on the high-osmolarity glycerol mitogen-activated protein kinase (HOG-MAPK) pathway, which regulates multiple physiological functions. BH (256 and 64 μg ml
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.